Johnson & Johnson

21 hours ago · prnewswire.com

Analysis shows ~87% of patients treated with TECVAYLI® plus DARZALEX FASPRO® as early as second line were estimated to have comparable mortality risk to the general population A separate analysis shows the survival benefit was driven by a 90% reduction in the risk of multiple myeloma progression versus standard of care, with no significant difference in rates of non-relapse mortality  Johnson & Johnson is advancing a differentiated multiple myeloma portfolio designed to deliver deeper, more durable disease control and improve long-term outcomes for patients  RARITAN, N.J., Sept. 23, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announced new data from the Phase 3 MajesTEC-3 study showing sustained disease control and survival with TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in patients with relapsed or refractory multiple myeloma (RRMM) who had received 1-3 prior lines of therapy.1,2 Using a relative survival mixture cure model (MCM) and actual progression-free survival (PFS) and overall survival (OS) data from the trial, statistical modeling estimated that ~87% of patients treated with TECVAYLI® plus DARZALEX FASPRO ®  (Tec-Dara) may experience a mortality risk and projected life expectancy similar to an age-matched general population.1 Modeling further predicted that median overall survival with Tec-Dara would be nearly four-fold longer than with the standard of care (SOC) comparator in the study, dexamethasone with pomalidomide or bortezomib (DPd/DVd).

1 day ago · zacks.com

J&J's Caplyta shows rapid and significant improvement in bipolar mania symptoms in a pivotal phase III study.

2 days ago · benzinga.com

Johnson & Johnson (NYSE:JNJ) on Monday reported topline results from its Phase 3 study evaluating Caplyta (lumateperone) for adults experiencing manic episodes linked to bipolar I disorder.

2 days ago · reuters.com

Johnson & Johnson said on Monday its experimental use of Caplyta for bipolar mania met the main goal ​of a late-stage study, bringing the drug a step ‌closer to expanding beyond its currently approved uses.

4 days ago · 247wallst.com

Retirement portfolios need income that shows up on time, grows faster than inflation, and does not blink during a downturn.

5 days ago · zacks.com

JNJ's growth gets a boost from new drug launches and pipeline wins, but Stelara's patent loss and MedTech headwinds remain key risks.

6 days ago · zacks.com

In the most recent trading session, Johnson & Johnson (JNJ) closed at $270.22, indicating a +1.1% shift from the previous trading day.

6 days ago · seekingalpha.com

Johnson & Johnson (JNJ) Presents at Deutsche Bank 2026 Healthcare Summit Transcript

6 days ago · marketbeat.com

Johnson & Johnson NYSE: JNJ Executive Vice President and Chief Financial Officer Joe Wolk said the company sees a path to growth above its previously stated 5% to 7% long-term range, supported by its pharmaceutical pipeline, medical technology portfolio and capital flexibility.

8 days ago · gurufocus.com

Johnson and Johnson (JNJ), the pharmaceutical and medical-technology giant, added another potentially important commercial argument for Caplyta, with new late-sta